Clinical characteristics and treatment outcomes of severe asthma patients with a history of multiple biologic drugs use
| Autor: | Kazuhiro Abe, Kiyoshi Takeyama, Mitsuko Kondo, Azusa Miyoshi, Etsuko Tagaya, Osamitsu Yagi, Soshi Muramatsu, Fumi Kobayashi, Tomohiro Akaba |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty Exacerbation medicine.drug_class business.industry media_common.quotation_subject Severe asthma Immunology Treatment outcome General Medicine medicine.disease Internal medicine Eosinophilic medicine Immunology and Allergy Corticosteroid Nasal polyps Airway business media_common |
| Zdroj: | Asian Pacific Journal of Allergy and Immunology. |
| ISSN: | 2228-8694 0125-877X |
| DOI: | 10.12932/ap-170221-1070 |
| Popis: | BACKGROUND Asthma control has been shown to improve after clinical use of molecular-targeted biologic drugs. Although most patients have shown favorable responses to biologic drugs, some individuals need to switch to another biologic drug. To date, limited data are available regarding patients who received multiple biologic drugs. OBJECTIVE We aimed to evaluate the characteristics and outcomes of patients treated with multiple biologic drugs. METHODS We reviewed severe asthma patients who received biologic drugs between May 2009 and September 2019. Clinical characteristics of patients and changes in annualized asthma exacerbation rates, asthma control test (ACT), and oral corticosteroid (OCS) dose, before and after the use of the final biologic drug, were evaluated. RESULTS Of the 105 patients who received biologic drugs, 20 patients received multiple biologic drugs. Twelve patients received two biologic drugs, six received three, and two received four. Patients who received multiple biologic drugs tended to have a significantly higher number of allergic or eosinophilic airway comorbidities (allergic rhinitis: p = 0.02, chronic rhinosinusitis with nasal polyps: p < 0.001). Approximately half of the patients changed to different treatments due to uncontrolled comorbidities. Annualized exacerbation rates, ACT, and OCS dose significantly improved after the latest biologic drug use (p = 0.035, p < 0.001, and p = 0.038, respectively). CONCLUSIONS The results of this study indicated that allergic and eosinophilic airway comorbidities should be considered during the selection of biologic drugs. Furthermore, most patients who received multiple biologic drugs achieved disease control after switching to the optimal biologic drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|